Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

wsj.com - Ben Dummett - Novartis Dealmaking Serves as Cautionary Tale for Pharma M&A
Novartis Dealmaking Serves as Cautionary Tale for Pharma M&A
Wall Street Journal

Novartis' latest trial setback serves a cautionary tale for investors betting on big pharma's strategy of making bite-size acquisitions to bolster their drug pipelines. In theory, smaller deals offer big pharma access to promising and potentially…

cnbc.com - Elsa Ohlen - Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat
Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat
CNBC

Sandoz CEO Richard Saynor warned U.S. patients could ultimately bear the cost of threatened tariffs on imported generic drugs. Saynor said manufacturers facing steep tariffs could be forced to raise prices or stop supplying some medicines. Sandoz…

seekingalpha.com - S&P Global Market Intelligence - Outsize Transaction Moves Private Equity Pharma Deals To $17.8B
Outsize Transaction Moves Private Equity Pharma Deals To $17.8B
Seeking Alpha

In July alone, the sector recorded a total transaction value of $3.74 billion, topping the second quarter's $3.21 billion. Deal volume, however, fell 11.0% year over year to 105 in the first seven months of 2026, according to Market Intelligence…

thehindu.com - Siddharth Kumar Singh - Hyderabad-Tashkent flight to strengthen tourism, pharma and healthcare ties, says envoy
Hyderabad-Tashkent flight to strengthen tourism, pharma and healthcare ties, says envoy
The Hindu

A new Hyderabad-Tashkent flight will be among the first tangible outcomes of a renewed push to deepen India-Uzbekistan ties, with Uzbekistan's Ambassador to India Sardor Mirzayusupovich Rustambaev describing the route as an ‘air bridge'…

marketbeat.com - NewAmsterdam Pharma (NASDAQ:NAMS) Given 'Buy' Rating at HC Wainwright
NewAmsterdam Pharma (NASDAQ:NAMS) Given 'Buy' Rating at HC Wainwright
MarketBeat

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report)'s stock had its 'buy' rating reiterated by HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $52.00 price objective on the…

marketbeat.com - TD Cowen Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price
TD Cowen Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price
MarketBeat

Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its price target boosted by equities researchers at TD Cowen from $65.00 to $68.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a 'buy' rating on the…

thehindubusinessline.com - Sun Pharma gets ratings boost from Moody's, S&P over ₹11.75-billion Organon & Co acquisition bid
Sun Pharma gets ratings boost from Moody's, S&P over ₹11.75-billion Organon & Co acquisition bid
BusinessLine

Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries -- India's largest pharmaceutical company -- over the proposed $11.75-billion acquisition of US-based Organon & Co. S&P Global Ratings assigned a…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) Shares Gap Down - What's Next?
Royalty Pharma (NASDAQ:RPRX) Shares Gap Down - What's Next?
MarketBeat

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report)'s stock price gapped down before the market opened on Tuesday. The stock had previously closed at $63.96, but opened at $59.21. Royalty Pharma shares last traded at $60.0940, with a volume of…

marketbeat.com - NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down - Should You Sell?
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down - Should You Sell?
MarketBeat

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) gapped down prior to trading on Tuesday. The stock had previously closed at $25.40, but opened at $24.02. NewAmsterdam Pharma shares last traded at $25.3180, with a volume…

seekingalpha.com - Albert Anthony - KBR: A Bet On Future Innovation And Global Scale, As Major Spinoff Looms (NYSE:KBR)
KBR: A Bet On Future Innovation And Global Scale, As Major Spinoff Looms (NYSE:KBR)
Seeking Alpha

Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…

statnews.com - Andrew Joseph - AstraZeneca's experimental COPD treatment posts strong results in late-stage studies
AstraZeneca's experimental COPD treatment posts strong results in late-stage studies
STAT

In a pair of late-stage trials, a drug from AstraZeneca reduced the dangerous flare-ups that drive the worsening of COPD, positioning it as a potential new option for the vast numbers of patients with the debilitating lung condition, according to…

rediff.com - Nandita Malik - Stock Markets Decline: Sensex, Nifty Fall on Rising Crude Oil Prices & US-Iran Hostilities
Stock Markets Decline: Sensex, Nifty Fall on Rising Crude Oil Prices & US-Iran Hostilities
Rediff.com

Indian stock markets, including the Sensex and Nifty, experienced a downturn in early trade, primarily driven by the surge in crude oil prices and persistent geopolitical tensions stemming from US-Iran hostilities in West Asia. Indian benchmark…

globenewswire.com - Cloverleaf Bio - Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics
Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics
GlobeNewswire

Cloverleaf Bio Raises $33 Million Seed Financing to Advance Novel RNA-Based Cancer Therapeutics Oversubscribed round led by 4BIO Capital includes strategic investment from AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund, reflecting…

seekingalpha.com - High Alpha Professor - Kodiak AI: The Stock Collapsed Just As The Business Started Working (NASDAQ:KDK)
Kodiak AI: The Stock Collapsed Just As The Business Started Working (NASDAQ:KDK)
Seeking Alpha

Kodiak AI earns a speculative buy as long-haul driverless commercialization nears, despite extreme cash burn and a going-concern warning. KDK's DaaS model shows promise with Atlas, but customer concentration and unproven broader demand remain key…

globenewswire.com - 4Bio Capital - 4BIO Capital leads oversubscribed $33 Million Seed Financing of Cloverleaf Bio, Advancing Novel RNA-Based Cancer Therapeutics
4BIO Capital leads oversubscribed $33 Million Seed Financing of Cloverleaf Bio, Advancing Novel RNA-Based Cancer Therapeutics
GlobeNewswire

4BIO Capital led upsized and oversubscribed round which includes strategic investment from AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund, reflecting depth of industry interest in this novel RNA therapeutics platform Financing will…

Receive a Daily briefing on Pharma Industry News

Get Started